Role of Urokinase-Type Plasminogen Activator Receptors as an Early Detector for Treatment Outcome in Adult Acute Myeloid Leukemia in Egyptian Patients

Tarek  Darwish; Amany M.  Helal; Hanan R.  Nassar; Soad A.  Eltokhy; Eman Z.  Kandeel; Laila A. E.  Hegazy

doi:10.4236/jct.2015.611104

JCT Vol.6 No.11 , October 2015

Role of Urokinase-Type Plasminogen Activator Receptors as an Early Detector for Treatment Outcome in Adult Acute Myeloid Leukemia in Egyptian Patients

Hanan R. Nassar¹^*, Eman Z. Kandeel², Laila A. E. Hegazy³, Amany M. Helal¹, Tarek Darwish¹, Soad A. Eltokhy²

Abstract: Background: The urokinase-type plasminogen activator system which consists of a proteinase (the urokinase-type plasminogen activator, uPA), a receptor (the urokinase-type plasminogen activator receptor uPAR or CD87) and inhibitors (PAI1) is enriched in several types of tumors and involved in proteolysis, cell migration and invasion. High expression of uPA and uPAR is associated with an increased relapse rate and shorter survival in breast cancer and colorectal carcinomas. Aims: This study shed light on the expression of uPAR in adult acute myeloid leukemia (AML) and its prognostic relevance. Methods: Peripheral blood and bone marrow samples are obtained from 54 newly diagnosed AML adult patients, 20 healthy controls stained with anti CD87 and estimated on flow cytometry. Results: CD87 expression was heterogeneous in different FAB subtypes of AML with high expression in monocytic leukemia (M4/M5) (P value 0.001). High expression of CD87 was associated with shorter survival and poor response to therapy (P = 0.028, 0.002 respectively). The most discriminating cut off value of CD87 expression was 20%, patients with less than 20% expression had 4.6 times better treatment outcome than those with more than or equal to 20%. On the multivariate analysis, CD87 was the most significant single variable that affect treatment outcome compared to total leucocytic count, hemoglobin level, platelets count, cytogenetic and FLT expression. Summary/Conclusion: High CD87 expression is an independent prognostic parameter associated with poor response and shorter overall survival in adult AML patients.

Keywords: AML, Plasminogen, Survival, uPAR, CD87

Cite this paper: Nassar, H. , Kandeel, E. , Hegazy, L. , Helal, A. , Darwish, T. and Eltokhy, S. (2015) Role of Urokinase-Type Plasminogen Activator Receptors as an Early Detector for Treatment Outcome in Adult Acute Myeloid Leukemia in Egyptian Patients. Journal of Cancer Therapy, 6, 963-970. doi: 10.4236/jct.2015.611104.

References

[1] Damm, F., Heuser, M., Morgan, M., Wagner, K., Gorlich, K., et al. (2011) Integrative Prognostic Risk Score in Acute Myeloid Leukemia with Normal Karyotype. Blood, 117, 4561-4568.
http://dx.doi.org/10.1182/blood-2010-08-303479

[2] Pollanen, J., Stephens, R.W. and Vaheri, A. (1991) Directed Plasminogen Activation at the Surface of Normal and Malignant Cells. Advances in Cancer Research, 57, 273-328.
http://dx.doi.org/10.1016/S0065-230X(08)61002-7

[3] Behrendt, N. and Stephens, R.W. (1998) The Urokinase Receptor. Fibrinolysis Proteolysis, 12, 191-204.

[4] Blasi, F. (1997) uPA, uPAR, PAI-1: Key Intersection of Proteolytic, Adhesive and Chemotactic Highways? Immunology Today, 18, 415-417.
http://dx.doi.org/10.1016/S0167-5699(97)01121-3

[5] Aguirre-Ghiso, J.A., Kovalski, K. and Ossowski, L. (1999) Tumor Dormancy Induced by Downregulation of Urokinase Receptor in Human Carcinoma Involves Integrin and MAPK Signaling. The Journal of Cell Biology, 147, 89-103.
http://dx.doi.org/10.1083/jcb.147.1.89

[6] Chapman, H.A. (1997) Plasminogen Activators, Integrins, and the Coordinated Regulation of Cell Adhesion and Migration. Current Opinion in Cell Biology, 9, 714-724.
http://dx.doi.org/10.1016/S0955-0674(97)80126-3

[7] Gyetko, M.R., Todd, R.F., Wilkinson, C.C. and Sitrin, R.G. (1994) The Urokinase Receptor Is Required for Human Monocyte Chemotaxis in Vitro. The Journal of Clinical Investigation, 93, 1380-1387.
http://dx.doi.org/10.1172/JCI117114

[8] Almeida, J. (1999) Extensive Characterization of the Immunophenotype and Pattern of Cytokine Production by Distinct Subpopulation of Normal Human Peripheral Blood MHC + Lineage Cells. Clinical & Experimental Immunology, 188, 392-409.
http://dx.doi.org/10.1046/j.1365-2249.1999.01078.x

[9] Plesner, T., Ralfkiaer, E., Wittrup, M., Ferrero, E., Bondanza, A., et al. (1994) Expression of the Receptor for Urokinase-Type Plasminogen Activator in Normal and Neoplastic Blood Cells and Hemopoietic Tissue. American Journal of Clinical Pathology, 102, 835-841.

[10] Ramage, J.G., Vallera, D.A., Black, J.H., Aplan, P.D., Kees, U.R., et al. (2003) The Diphtheria Toxin/Urokinase Fusion Protein (DTAT) Is Selectively Toxic to CD87 Expressing Leukemic Cells. Leukemia Research, 27, 79-84.
http://dx.doi.org/10.1016/S0145-2126(02)00077-2

[11] Schlossman, S., Boumsell, L., Gilks, W., Harlan, J.M., Kishimoto, T., Morimoto, C., Ritz, J., Shaw, S. and Silverstein, R. (1995) Leucocyte Typing V: White Cell Differentiation Antigens. Oxford University Press, New York.

[12] de Bock, C.E., Lin, Z., Itoh, T., Morris, D., Murrell, G. and Wang, Y. (2005) Inhibition of Urokinase Receptor Gene Expression and Cell Invasion by Anti-uPAR DNAzymes in Osteosarcoma Cells. FEBS Journal, 272, 3572-3582.
http://dx.doi.org/10.1111/j.1742-4658.2005.04778.x

[13] Han, B., Nakamura, M., Zhou, G.Y., Ishii, A., Nakamura, A., Bai, Y.H., et al. (2006) Calcitonin Inhibits Invasion of Breast Cancer Cells: Involvement of Urokinase-Type Plasminogen Activator (UPA) and uPA Receptor. International Journal of Oncology, 28, 807-814.
http://dx.doi.org/10.3892/ijo.28.4.807

[14] Bene, M.C., Castoldi, G., Knapp, W., Rigolin, G.M., Escribano, L., Lemez, P., et al. (2004) CD87 (Urokinase-Type Plasminogen Activator Receptor), Function and Pathology in Hematological Disorders: A Review. Leukemia, 18, 394-400.

[15] Graf, M., Reif, S., Hecht, K., Pelka-Fleischer, R., Pfister, K. and Schmetzer, H. (2005) High Expression of Urokinase Plasminogen Activator Receptor (UPA-R) in Acute Myeloid Leukemia (AML) Is Associated with Worse Prognosis. American Journal of Hematology, 79, 26-35.
http://dx.doi.org/10.1002/ajh.20337

[16] Lanza, F., Matutes, E., Orfao, A., Knapp, W., Bene, M.C., et al. (1998) Expression and Functional Role of Urokinase-Type Plasminogen Activator Receptor in Normal and Acute Leukemic Cells. British Journal of Haematology, 103, 110-123.
http://dx.doi.org/10.1046/j.1365-2141.1998.00932.x

[17] Atfy, M., Eissa, M., Salah, H.E. and El Shabrawy, D.A. (2012) Role of Urokinase Plasminogen Activator Receptor (CD87) as a Prognostic Marker in Acute Myeloid Leukemia. Medical Oncology, 29, 2063-2069.
http://dx.doi.org/10.1007/s12032-011-9993-x

[18] Knapp, W., Strobl, H. and Majdic, O. (1994) Flow Cytometric Analysis of Cell Surface and Intracellular Antigens in Leukemia Diagnosis. Cytometry, 18, 187-198.
http://dx.doi.org/10.1002/cyto.990180402

[19] Aref, S., El-Sherbiny, M., Mabed, M., Menessy, A. and El-Rafaei, M. (2003) Urokinase Plasminogen Activator Receptor and Soluble Matrix Metalloproteinase 9 in Acute Myeloid Leukemia Patients: A Possible Relation to Disease Invasion. Hematology, 8, 385-391.
http://dx.doi.org/10.1080/10245330310001621323

[20] Nadir, Y., Katz, T., Sarig, G., Hoffman, R., Oliven, A., Rowe, J.M., et al. (2005) Hemoststic Balance on the Surface of Leukemic Cells: The Role of Tissue Factor and Urokinase Plasmiongen Activator Receptor. Haematologica, 90, 1549-1556.

[21] Scherrer, A., Wohlwend, A., Kruithof, E.K.O., Vassalli, J.-D. and Sappino, A.-P. (1999) Plasminogen Activation in Human Acute Leukaemias. British Journal of Haematology, 105, 920-927.
http://dx.doi.org/10.1046/j.1365-2141.1999.01432.x

[22] Plesner, T., Ralfkiaer, E., Wittrup, M., Johnsen, H., Pyke, C., Pedersen, T.L., et al. (1994) Expression of the Receptor for Urokinase-Type Plasminogen Activator in Normal and Neoplastic Blood Cells and Hemopoietic Tissue. American Journal of Clinical Pathology, 102, 835-884.

[23] Jardi, M., Ingles-Esteve, J., Burgal, M., Azqueta, C., Velsaco, F., López-Pedrera, C., et al. (1996) Distinct Patterns of Urokinase Receptor (uPAR) Expression by Leukemic Cells and Peripheral Blood Cells. Thrombosis and Haemostasis, 76, 1009-1019.

[24] Rigolin, G.M., Tieghi, A., Ciccone, M., Bragotti, L.Z., Cavazzini, F., Della Porta, M., et al. (2003) Soluble Urokinasetype Plasminogen Activator Receptor (suPAR) as an Independent Factor Predicting Worse Prognosis and Extra-Bone Marrow Involvement in Multiple Myeloma Patients. British Journal of Haematology, 120, 953-959.
http://dx.doi.org/10.1046/j.1365-2141.2003.04176.x

[25] Sawai, H., Okada, Y., Funahashi, H., Matsuo, Y., Takahashi, H., Takeyama, H. and Manabe, T. (2006) Interleukin-1α Enhances the Aggressive Behavior of Pancreatic Cancer Cells by Regulating the α6β1-Integrin and Urokinase Plasminogen Activator Receptor Expression. BMC Cell Biology, 7, 8.